[HTML][HTML] Genetic markers in triple-negative breast cancer

Z Sporikova, V Koudelakova, R Trojanec… - Clinical breast cancer, 2018 - Elsevier
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …

Cyclin-dependent kinases (CDK) and their role in diseases development–review

P Łukasik, M Załuski, I Gutowska - International journal of molecular …, 2021 - mdpi.com
Cyclin-dependent kinases (CDKs) are involved in many crucial processes, such as cell cycle
and transcription, as well as communication, metabolism, and apoptosis. The kinases are …

Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer

NC Turner, Y Liu, Z Zhu, S Loi, M Colleoni… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE A large-panel gene expression analysis was conducted to identify biomarkers
associated with the effectiveness of adding palbociclib to fulvestrant. METHODS The …

Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity

M Arora, J Moser, TE Hoffman, LP Watts, M Min… - Cell, 2023 - cell.com
CDK2 is a core cell-cycle kinase that phosphorylates many substrates to drive progression
through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an …

Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update

S Tadesse, EC Caldon, W Tilley… - Journal of medicinal …, 2018 - ACS Publications
Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S-and M-phases
of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is …

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

L Harris, H Fritsche, R Mennel, L Norton… - Journal of clinical …, 2007 - ascopubs.org
Purpose To update the recommendations for the use of tumor marker tests in the prevention,
screening, treatment, and surveillance of breast cancer. Methods For the 2007 update, an …

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

Y Wang, JGM Klijn, Y Zhang, AM Sieuwerts, MP Look… - The Lancet, 2005 - thelancet.com
Background Genome-wide measures of gene expression can identify patterns of gene
activity that subclassify tumours and might provide a better means than is currently available …

Overview of resistance to systemic therapy in patients with breast cancer

AM Gonzalez-Angulo, F Morales-Vasquez… - Breast cancer …, 2007 - Springer
Breast cancer is the most common cancer and the second leading cause of cancer death in
American women. It was the second most common cancer in the world in 2002, with more …

Current and emerging biomarkers in breast cancer: prognosis and prediction

MT Weigel, M Dowsett - Endocrine-related cancer, 2010 - erc.bioscientifica.com
Breast cancer treatment has experienced several changes in the past decades due to the
discovery of specific prognostic and predictive biomarkers that enable the application of …

Cyclin-dependent kinase pathways as targets for cancer treatment

GI Shapiro - Journal of clinical oncology, 2006 - ascopubs.org
Cyclin-dependent kinases (cdks) are critical regulators of cell cycle progression and RNA
transcription. A variety of genetic and epigenetic events cause universal overactivity of the …